Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial
E Scarlato, V Merz, S Pietrobono, S Casalino, A Quinzii, C Zecchetto, L Mendo, S Giacomazzi, A Bonato, V De Vita, G Butturini, R Salvia, D Melisi · 2026
Read Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial by E Scarlato, V Merz, S Pietrobono, S Casalino, A Quinzii, C Zecchetto, L Mendo, S Giacomazzi, A Bonato, V De Vita, G Butturini, R Salvia, D Melisi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13157054.txt.
Description
Scarlato and co-authors update a trial that wraps pancreatic cancer surgery in a four-drug chemotherapy net, and hunt blood clues for who benefits. Resectable pancreatic cancer still lacks a settled plan around the operation. The nITRO trial gave NALIRIFOX before and after surgery. With about fifty months of follow-up, median survival reached thirty-two months across all enrolled patients and forty-eight among those resected.
The update adds detective work. High starting levels of the cytokine TNF-alpha marked patients who responded worse, reached surgery less often, and died sooner. Inherited faults in DNA repair and tumor suppressor genes also shaped outcomes. The authors argue such markers could one day sort patients toward, or away from, this demanding regimen.
Catalog record
| CREATOR | E Scarlato, V Merz, S Pietrobono, S Casalino, A Quinzii, C Zecchetto, L Mendo, S Giacomazzi, A Bonato, V De Vita, G Butturini, R Salvia, D Melisi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |